" /> Tifcemalimab - CISMeF





Preferred Label : Tifcemalimab;

NCIt synonyms : Anti-B- and T-lymphocyte Attenuator Monoclonal Antibody TAB004; Anti-BTLA Monoclonal Antibody TAB004; Icatolimab;

NCIt definition : A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).;

UNII : D40H7X1YZ0;

CAS number : 2236068-83-8;

Molecule name : JS 004; TAB-004; TAB 004; JS-004;

NCI Metathesaurus CUI : CL1378714;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
09/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.